Capital Advisors Ltd’s Cullinan Therapeutics CGEM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$25K Hold
1,600
– – ﹤0.01% 651
2026
Q2
$29K Hold
1,600
– – ﹤0.01% 608
2026
Q1
$23K Buy
+1,600
New +$20.6K ﹤0.01% 629
2023
Q4
– Sell
-37
Closed – – 1313
2023
Q3
$0 Hold
37
– – ﹤0.01% 1302
2023
Q2
$0 Hold
37
– – ﹤0.01% 1314
2023
Q1
$0 Hold
37
– – ﹤0.01% 1236
2022
Q4
$0 Hold
37
– – ﹤0.01% 1260
2022
Q3
$0 Hold
37
– – ﹤0.01% 1267
2022
Q2
$0 Buy
+37
New +$420 ﹤0.01% 1038

Other funds holding CGEM

Capital Advisors Ltd's CGEM Position: Q3 2026 in Review

Capital Advisors Ltd held its Cullinan Therapeutics (CGEM) position steady in Q3 2026 at 1,600 shares worth $25K. The position accounts for ﹤0.01% of the portfolio, ranked #651.

Capital Advisors Ltd first reported a position in CGEM in Q2 2022 and has held it in 9 quarters since. The position peaked at $29K in Q2 2026. 182 funds tracked by Wall St. Rank hold CGEM as of Q3 2026.

  • Capital Advisors Ltd held 1,600 shares of Cullinan Therapeutics worth $25K as of Q3 2026.
  • Capital Advisors Ltd left its Cullinan Therapeutics share count unchanged in Q3 2026.
  • Cullinan Therapeutics made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q3 2026, its #651 holding.
  • Capital Advisors Ltd first reported a position in Cullinan Therapeutics in Q2 2022 and has held it in 9 quarters since.
  • Capital Advisors Ltd's Cullinan Therapeutics position peaked at $29K in Q2 2026.
  • 182 funds tracked by Wall St. Rank held Cullinan Therapeutics as of Q3 2026.

Based on Capital Advisors Ltd's 13F filing for Q3 2026, filed 27 Oct 2026.